Stem Cell Sciences [ASX: STC] has licensed technology developed at Cambridge University used to reprogram adult cells into stem cells.

The agreement relates specifically to patents for technology used to generate induced pluripotent stem (iPS) cells from mammalian cells.

The technology was developed by Professor Austin Smith. Smith, director of the Wellcome Trust Centre for Stem Cell Research.

Smith also serves as chairman of SCS's Scientific Advisory Board.